Both HYDROBLOOD projects (Phase 1 and Phase 2) focus exclusively on developing an industrial plant for DHP production from animal blood.
TALLERES AZUARA SL
Spanish SME producing Decolourised Hydrolysed Protein from animal blood via a proprietary EU-validated industrial processing plant.
Their core work
Talleres Azuara is a Spanish SME based in Valls (Tarragona) that develops and manufactures industrial processing equipment for the food and agri-food sector. Their documented H2020 work centers on building a proprietary processing plant to produce Decolourised Hydrolysed Protein (DHP) from animal blood — a high-value protein ingredient recovered from slaughterhouse byproducts. The company successfully progressed through the EU's competitive SME Instrument programme, winning both Phase 1 feasibility funding and a large Phase 2 innovation grant for the same technology, signalling strong commercial validation. Their background in mechanical workshops ("talleres") suggests in-house capability in custom equipment fabrication and process engineering.
What they specialise in
HYDROBLOOD targets the conversion of blood — a low-value slaughter byproduct — into a marketable food or feed protein ingredient, a core circular-economy application.
The HYDROBLOOD Phase 2 grant of ~€2M supports the development of a full processing plant, consistent with an engineering firm designing and building custom food-sector machinery.
Successfully coordinating both SME Instrument Phase 1 (feasibility) and Phase 2 (market-ready innovation) demonstrates capacity to manage EU-funded R&D from concept to pilot scale.
How they've shifted over time
Talleres Azuara's entire H2020 record is a single technology trajectory: the HYDROBLOOD project pursued in two sequential phases between 2016 and 2019. Phase 1 (2016, €50,000) was a feasibility and business case study, while Phase 2 (2017–2019, ~€2M) moved into full development and pilot plant construction. There is no visible pivot or broadening — this organisation committed deeply to one specific innovation and followed it through the SME Instrument pipeline from idea to market-ready solution. The absence of subsequent H2020 projects suggests either that commercialisation of HYDROBLOOD became their primary focus after 2019, or that they did not pursue further EU funding once the technology was developed.
Their trajectory points toward a company that has completed its R&D phase and is now in commercial deployment of DHP production technology — a potential partner for licensing, joint ventures, or supply of processing equipment rather than for new research consortia.
How they like to work
Talleres Azuara operated exclusively as project coordinator across both H2020 projects, which for SME Instrument grants is standard — these are single-company innovation grants rather than multi-partner consortia. As a result, they show zero consortium partners in the H2020 record, meaning there is no evidence of their behaviour within multi-actor research teams. Any future collaboration would likely be their first experience working inside a larger EU consortium, which is worth factoring into partnership planning.
Talleres Azuara has no recorded consortium partners from their H2020 participation, as both projects were solo SME Instrument grants. Their network footprint within the EU research ecosystem is effectively a blank slate — there are no established co-applicant relationships to leverage.
What sets them apart
Talleres Azuara holds a rare combination: hands-on manufacturing capability ("talleres") paired with a validated, EU-funded proprietary process for producing food-grade protein from slaughterhouse blood waste. Few companies in the Iberian agri-food equipment space have taken a byproduct valorisation technology all the way through the SME Instrument's Phase 1 + Phase 2 gauntlet, which implies a credible business case and a working pilot. For a consortium needing a specialist in animal-derived protein recovery or circular food chain processing, they offer both the engineering know-how and a proven technology asset.
Highlights from their portfolio
- HYDROBLOODPhase 2 grant of nearly €2M — one of the larger SME Instrument awards — validates the commercial potential of their proprietary DHP processing technology and marks them as a credible deep-tech SME in food protein recovery.
- HYDROBLOODThe Phase 1 feasibility award (2016) confirmed market viability and directly unlocked the larger Phase 2 grant, demonstrating a disciplined innovation-to-market progression unusual for a small manufacturing workshop.